Effects of hypertension on cerebral cortical thickness alterations in patients with type 2 diabetes

Published:October 05, 2019DOI:


      • HTN may accelerate cortical thickness reduction in T2DM patients.
      • T2DM showed cognitive dysfunction and elevated CRP level.
      • HTN, Insulin resistance and blood lipid are associated with CT alterations in T2DM patients.



      Although hypertension (HTN) is the high comorbidity of Type 2 diabetes mellitus (T2DM) and known to be a vascular risk factor for brain damage, the effects of HTN on brain function in T2DM patients are not well understood. Present study was performed to investigate whether HTN might accelerate the Cerebral cortical thickness (CT) alterations in patients with T2DM.


      We enrolled 35 participants with only T2DM, 25 T2DM patients with HTN (HT2DM) and 28 healthy controls (HCs). The cognitive function was assessed and brain image data was collected then the CT was calculated for each participant. Partial correlations between the CT of each brain region and standard laboratory testing data and neuropsychological scale scores were also analyzed. Multivariable regression analysis was performed to evaluated the vascular risk factors and brain regions with different CT in HT2DM patients.


      Cognitive impairment is associated with thinning of the cerebral cortical thickness reduction in T2DM patients. CT thinning in the left inferior parietal lobe, left posterior cingulate and right precuneus were observed in HT2DM group relative to only T2DM group. Furthermore, the CT decreasing in the right precuneus was negatively correlated with duration of HTN.


      The current study revealed that coexistent HTN may accelerate the CT reduction in T2DM patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wang L.
        • Gao P.
        • Zhang M.
        • Huang Z.
        • Zhang D.
        • et al.
        Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013.
        JAMA. 2017; 317: 2515-2523
        • Klein J.P.
        • Waxman S.G.
        • et al.
        The brain in diabetes: molecular changes in neurons and their implications for end-organ damage.
        Lancet Neurol. 2003; 548–554
        • Biessels G.J.
        • Staekenborg S.
        • Brunner E.
        • et al.
        Risk of dementia in diabetes mellitus: a systematic review.
        Lancet Neurol. 2006; 5: 64-74
        • Strachan M.W.
        • Reynolds R.M.
        • Marioni R.E.
        • et al.
        Cognitive function, dementia and type 2 diabetes mellitus in the elderly.
        Nat Rev Endocrinol. 2011; 7: 108-114
        • Li C.
        • Li C.
        • Yang Q.
        • et al.
        Cortical thickness contributes to cognitive heterogeneity in patients with type 2 diabetes mellitus.
        Medicine (Baltimore). 2018; 97e10858
      1. American Heart Association. Cardiovascular disease & diabetes. 2015 [Accessed 30 Nov 2017].

        • Lopez-Jaramillo P.
        • Lopez-Lopez J.
        • Lopez-Lopez C.
        • et al.
        The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice.
        Diabetol Metab Syndr. 2014; 6: 31
        • Niermeyer M.A.
        Cognitive and gait decrements among non-demented older adults with Type 2 diabetes or hypertension: a systematic review.
        Clin Neuropsychol. 2018; 32: 1256-1281
        • Wenqing X.
        • Hengyi R.
        • Andrea M.S.
        • Rong H.
        • Sai T.
        • et al.
        Blood pressure is associated with cerebral blood flow alterations in patients with T2DM as revealed by perfusion functional MRI.
        Medicine (Baltimore). 2018; 94e2231
        • Moran C.
        • Beare R.
        • Phan T.G.
        • Bruce D.G.
        • Callisaya M.L.
        • Srikanth V.
        Alzheimer's Disease Neuroimaging Initiative (ADNI). Type 2 diabetes mellitus and biomarkers of neurodegeneration.
        Neurology. 2015; 85: 1123-1130
        • Rast P.
        • Kennedy K.M.
        • Rodrigue K.M.
        • Robinson P.R.A.W.
        • Gross A.L.
        • et al.
        APOEε4 genotype and hypertension modify 8-year cortical thinning: five occasion evidence from the seattle longitudinal study.
        Cereb Cortex. 2018; 28: 1934-1945
        • Peng B.
        • Chen Z.
        • Ma L.
        • et al.
        Cerebral alterations of type 2 diabetes mellitus on MRI: A pilot study.
        Neurosci Lett. 2015; 606: 100-105
        • Leritz E.C.
        • Salat D.H.
        • Williams V.J.
        • et al.
        Thickness of the human cerebral cortex is associated with metrics of cerebrovascular health in a normative sample of community dwelling older adults.
        Neuroimage. 2011; 54: 2659-2671
        • Vuorinen M.
        • Kareholt I.
        • Julkunen V.
        • et al.
        Changes in vascular factors 28 years from midlife and late-life cortical thickness.
        Neurobiol Aging. 2013; 34: 100-109
        • Simon R.C.
        • Donald M.L.
        • Stuart J.R.
        • Mark E.B.
        • Mathew A.H.
        • et al.
        Associations between vascular risk factors and brain MRI indices in UK Biobank.
        Eur Heart J. 2019; 40: 2290-2300
        • Tchistiakova E.
        • Anderson N.D.
        • Greenwood C.E.
        • et al.
        Combined effects of type 2 diabetes and hypertension associated with cortical thinning and impaired cerebrovascular reactivity relative to hypertension alone in older adults.
        Neuroimage Clin. 2014; 5: 36-41
        • Pangman V.C.
        • Sloan J.
        • Guse L.
        An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice.
        Appl Nurs Res. 2000; 13: 209-213
        • Lafont S.
        • Marin-Lamellet C.
        • Paire-Ficout L.
        • et al.
        The Wechsler Digit Symbol Substitution Test as the best indicator of the risk of impaired driving in Alzheimer disease and normal aging.
        Dement Geriatr Cogn Disord. 2010; 29: 154-163
        • Williams J.B.
        Standardizing the Hamilton Depression Rating Scale: past, present, and future.
        Eur Arch Psychiatry Clin Neurosci. 2001; 251: II6-12
        • Shear M.K.
        • Vander Bilt J.
        • Rucci P.
        • et al.
        Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A).
        Depress Anxiety. 2001; 13: 166-178
        • Zhou C.
        • Xu J.
        • Ping L.
        • et al.
        Cortical thickness and white matter integrity abnormalities in obsessive-compulsive disorder: A combined multimodal surface-based morphometry and tract-based spatial statistics study.
        Depress Anxiety. 2018; 35: 742-751
        • Fischl B.
        • Dale A.M.
        Measuring the thickness of the human cerebral cortex from magnetic resonance images.
        Proc Natl Acad Sci USA. 2000; 97: 11050-11055
        • Fischl B.
        • van der Kouwe A.
        • Destrieux C.
        • et al.
        Automatically parcellating the human cerebral cortex.
        Cereb. 2004; 14: 11-22
        • Segonne F.
        • Pacheco J.
        • Fischl B.
        Geometrically accurate topology-correction of cortical surfaces using nonseparating loops.
        IEEE Trans Med Imaging. 2007; 26: 518-529
        • Desikan R.S.
        • Segonne F.
        • Fischl B.
        • et al.
        An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest.
        Neuroimage. 2006; 31: 968-980
        • Matthews D.R.
        • Hosker J.P.
        • Rudenski A.S.
        • et al.
        Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
        Diabetologia. 1985; 28: 412-419
        • Walker K.A.
        • Sharrett A.R.
        • Wu A.
        • Gottesman R.F.
        • et al.
        Association of midlife to late-life blood pressure patterns with incident dementia.
        JAMA. 2019; 322: 535-545
      2. SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, Wright CB, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321:553–61.

        • Power M.C.
        • Schneider A.L.
        • Wruck L.
        • Gottesman R.F.
        • et al.
        Life-course blood pressure in relation to brain volumes.
        Alzheimers Dement. 2016; 12: 890-899
        • Petrova M.
        • Prokopenko S.
        • Pronina E.
        • et al.
        Diabetes type 2, hypertension and cognitive dysfunction in middle age women.
        J Neurol Sci. 2010; 299: 39-41
        • Yoon S.
        • Cho H.
        • Kim J.
        • et al.
        Brain changes in overweight/obese and normal-weight adults with type 2 diabetes mellitus.
        Diabetologia. 2017; 60: 1207-1217
        • Ghasemi R.
        • Dargahi L.
        • Haeri A.
        • et al.
        Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.
        Mol Neurobiol. 2013; 47: 1045-1065
        • Biessels G.J.
        • van der Heide L.P.
        • Kamal A.
        • et al.
        Ageing and diabetes: implications for brain function.
        Eur J Pharmacol. 2002; 441: 1-14
        • Freiherr J.
        • Hallschmid M.
        • Frey 2nd, W.H.
        • et al.
        Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidenc.
        CNS Drugs. 2013; 27: 505-514